Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Neuroendocrine cancer

CABINET presents cabozantinib as a new treatment option for NETs

Nature Reviews Clinical Oncology volume 21, page 766 (2024)Cite this article

Subjects

Access through your institution
Buy or subscribe

Patients with advanced-stage neuroendocrine tumours (NETs) have limited treatment options following disease progression after 1–2 lines of systemic therapy. Now, newly published data from the phase III CABINET trial, simultaneously presented at the ESMO Congress 2024, demonstrate the efficacy of cabozantinib in this setting.

In CABINET, patients with locally advanced or metastatic well or moderately differentiated extrapancreatic (n = 203) or pancreatic (n = 95) NETs previously treated with at least one FDA-approved systemic therapy were randomly assigned, 2:1, to either cabozantinib or placebo. Most patients had received 177Lu-dotatate (~59%) and/or everolimus (~72%), and ~26% of those with pancreatic NETs had received sunitinib. Progression-free survival (PFS) was the primary end point.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. CABINET presents cabozantinib as a new treatment option for NETs. Nat Rev Clin Oncol 21, 766 (2024). https://doi.org/10.1038/s41571-024-00949-0

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41571-024-00949-0

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing